Schober, SJ; Steinhauser, M; Wawer, A; Teichert-von Luettichau, I; Salat, C; Issels, RD; Schwinger, W; Ussowicz, M; Antunovic, P; Castagna, L; Kolb, HJ; Burdach, SEG; Thiel, U.
Donor lymphocyte infusion after allogeneic stem cell transplantation is a feasible therapy option with acceptable toxicity rates in patients with refractory Ewing's sarcoma and rhabdomyosarcoma
CANCER RES. 2018; 78(19):
Doi: 10.1158/1538-7445.PEDCA17-A28
Web of Science
FullText
FullText_MUG